

LA JOLLA PHARMACEUTICAL CO  
Form 8-K  
May 22, 2006

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

May 18, 2006

La Jolla Pharmaceutical Company

(Exact name of registrant as specified in its charter)

Delaware

0-24274

33-0361285

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

6455 Nancy Ridge Drive, San Diego,  
California

92121

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(858) 452-6600

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 1.01 Entry into a Material Definitive Agreement.**

On May 18, 2006, La Jolla Pharmaceutical Company held its annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the stockholders approved an amendment to the La Jolla Pharmaceutical Company 1995 Employee Stock Purchase Plan (the "Plan"). The amendment increased the number of shares available for purchase under the Plan by 160,000 shares. The Plan, as amended, is filed as Exhibit 10.1 to this report.

**Item 8.01 Other Events.**

On May 18, 2006, the board of directors approved the composition of its committees as follows: Audit Committee: Stephen M. Martin (Chairman), Thomas H. Adams, Ph.D., and Craig R. Smith, M.D.; Compensation Committee: Robert A. Fildes, Ph.D. (Chairman), Dr. Adams, Mr. Martin, Martin P. Sutter, and James N. Topper, M.D., Ph.D.; Corporate Governance and Nominating Committee: Dr. Smith (Chairman), Nader J. Naini, and Frank E. Young, M.D., Ph.D.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit No. Description

10.1 La Jolla Pharmaceutical Company 1995 Employee Stock Purchase Plan, as amended.

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

La Jolla Pharmaceutical Company

May 19, 2006

By: */s/ Gail A. Sloan*

---

*Name: Gail A. Sloan*

*Title: Vice President of Finance and Secretary*

---

**Top of the Form**

Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
10.1	La Jolla Pharmaceutical Company 1995 Employee Stock Purchase Plan, as amended.